Get the Stockscreener App
7.78
0.65%
0.05
After Hours:
7.96
0.18
+2.31%
Nuvectis Pharma Inc stock is traded at $7.78, with a volume of 111.79K.
It is up +0.65% in the last 24 hours and up +0.52% over the past month.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
See More
Previous Close:
$7.73
Open:
$7.76
24h Volume:
111.79K
Relative Volume:
0.74
Market Cap:
$162.55M
Revenue:
-
Net Income/Loss:
$-22.38M
P/E Ratio:
-5.5177
EPS:
-1.41
Net Cash Flow:
$-15.54M
1W Performance:
-0.26%
1M Performance:
+0.52%
6M Performance:
+18.78%
1Y Performance:
+17.52%
1-Day Range:
$7.48
$7.87
1-Week Range:
$7.48
$8.15
52-Week Range:
$4.44
$11.80
Nuvectis Pharma Inc Stock (NVCT) Company Profile
Name
Nuvectis Pharma Inc
Sector
Industry
Phone
360-837-7232
Address
1 BRIDGE PLAZA, SUITE 275, FORT LEE
Compare NVCT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVCT
Nuvectis Pharma Inc
|
7.78 | 161.51M | 0 | -22.38M | -15.54M | -1.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 122.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 31.91B | 3.81B | -644.79M | -669.77M | -6.24 |
Nuvectis Pharma Inc Stock (NVCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-02-25 | Initiated | Maxim Group | Buy |
| Mar-17-25 | Initiated | Laidlaw | Buy |
| Jul-13-22 | Initiated | Ladenburg Thalmann | Buy |
Nuvectis Pharma Inc Stock (NVCT) Latest News
Why Nuvectis Pharma Inc. stock is on top investor watchlistsSkyrocketing investment returns - jammulinksnews.com
Nuvectis Pharma Inc. Stock Analysis and ForecastSuperior returns - Autocar Professional
What drives Nuvectis Pharma Inc. stock priceRecord-breaking capital gains - Autocar Professional
What analysts say about Nuvectis Pharma Inc. stockUnstoppable profit momentum - PrintWeekIndia
Is Nuvectis Pharma Inc. a good long term investmentTremendous wealth creation - jammulinksnews.com
(NVCT) On The My Stocks Page - news.stocktradersdaily.com
Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights - sg.finance.yahoo.com
How Nuvectis Pharma Inc. stock performs during market volatilityFree Growth Investment Group - Newser
What makes Nuvectis Pharma Inc. stock price move sharplyHigh Confidence Trade Setups - Newser
Why Nuvectis Pharma Inc. stock attracts strong analyst attentionProfitable Yet Secure Picks - Newser
When (NVCT) Moves Investors should Listen - news.stocktradersdaily.com
Nuvectis reports positive drug interaction study for cancer drug NXP900 By Investing.com - Investing.com Nigeria
Nuvectis Pharma, Inc. Announces Successful Completion of A Drug-Drug Interaction Study in Healthy Volunteers - MarketScreener
Nuvectis Pharma Announces Successful Completion of a Drug-Drug Interaction Study in Healthy Volunteers Supporting NXP900's Potential as a Combination Partner with Leading Therapies - GlobeNewswire
Nuvectis Pharma, Inc. (NASDAQ:NVCT) Shares Purchased by Oppenheimer & Co. Inc. - Defense World
(NVCT) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Nuvectis Pharma, Inc.(NasdaqCM: NVCT) added to Russell 3000 Index - MarketScreener
Nuvectis Pharma (NASDAQ:NVCT) Lowered to “Sell” Rating by Wall Street Zen - Defense World
Is Nuvectis Pharma, Inc. technically bullish or bearish? - MarketsMojo
(NVCT) Proactive Strategies - news.stocktradersdaily.com
Silicon Valley - FinancialContent
Nuvectis Pharma: Still Interesting, But Still Too Risky To Jump In - Seeking Alpha
Insiders of Nuvectis Pharma, Inc. (NASDAQ:NVCT) must be disappointed as stock fell 10% after recent purchases - Yahoo Finance
Insider Stock Buying Of Nuvectis Pharma Delivers Return On US$2.19m Investment - simplywall.st
Nuvectis Pharma Approves Proposals at Annual Meeting - TipRanks
Nuvectis Pharma Inc Stock (NVCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Nuvectis Pharma Inc Stock (NVCT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mosseri Marlio Charles | 10% Owner |
Jun 18 '25 |
Buy |
8.05 |
28,043 |
225,746 |
2,976,203 |
| Mosseri Marlio Charles | 10% Owner |
Jun 17 '25 |
Buy |
8.11 |
5,399 |
43,786 |
2,948,160 |
| Mosseri Marlio Charles | 10% Owner |
May 12 '25 |
Buy |
8.11 |
21,167 |
171,664 |
2,942,761 |
| Mosseri Marlio Charles | 10% Owner |
May 06 '25 |
Buy |
8.59 |
12,444 |
106,955 |
2,896,565 |
| Mosseri Marlio Charles | 10% Owner |
May 07 '25 |
Buy |
8.59 |
12,317 |
105,770 |
2,908,882 |
| Mosseri Marlio Charles | 10% Owner |
May 08 '25 |
Buy |
8.65 |
2,650 |
22,922 |
2,911,532 |
| Mosseri Marlio Charles | 10% Owner |
Feb 07 '25 |
Buy |
5.00 |
240,000 |
1,200,000 |
2,884,121 |
| BENTSUR RON | Chairman & CEO |
Dec 24 '24 |
Buy |
4.65 |
4,500 |
20,925 |
3,270,924 |
| Mosseri Marlio Charles | 10% Owner |
Dec 13 '24 |
Buy |
4.70 |
17,000 |
79,900 |
2,612,000 |
| Poradosu Enrique | Chief Science & Business Off |
Nov 19 '24 |
Buy |
4.99 |
2,000 |
9,980 |
1,506,319 |
0.97%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):